Drugs / GEN-003
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01667341 | Jul 2012 → May 2014 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT03146403 | May → Dec 2017 | genital herpes, herpes simplex type 2 infectious disease | Genocea Biosciences, Inc. | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT02515175 | Nov 2015 → Jul 2016 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02300142 | Jan 2015 → Jun 2016 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02114060 | Jul 2014 → Feb 2016 | genital herpes simplex type 2 infectious disorder | Genocea Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02114060 ↗ |
| Modality | Vaccine | “GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2∆TMR and ICP4.2, and Matrix-M2 adjuvant.” PMID 28329211 ↗ Mar 2017 |
| Route | Intramuscular | “IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).” NCT01667341 ↗ |